Skip to main content
Log in

Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The plasma and urine pharmacokinetic parameters of pyrazinamide and of its metabolites (pyrazinoic acid, 5-hydroxy-pyrazinamide, 5-hydroxy-pyrazinoic acid and pyrazinuric acid) have been studied after a single oral dose of pyrazinamide 27 mg · kg−1 in 9 healthy subjects.

Pyrazinamide was rapidly absorbed (tmax ≤1 h) and showed a short distribution phase followed by an elimination phase of t1/2β=9.6 h. The close similarity of the apparent elimination rates of the metabolites led to a second trial of a single oral dose of pyrazinoic acid to evaluate the formation and elimination stages.

The limiting factor was found to be the activity of a microsomal deamidase (pyrazinoic acid formation from pyrazinamide and 5-hydroxy-pyrazinoic acid formation from 5-hydroxy-pyrazinamide). In contrast, oxidation by xanthine oxidase occurred very rapidly (5-hydroxy-pyrazinamide formation and pyrazinoic acid catabolism to 5-hydroxy-pyrazinoic acid).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kushner S, Dalalian H, Sanjurjo JL, Bach FL, Safir SR Jr, Smith VKJ, Williams JH (1952) Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamide and related compounds. J Am Chem Soc 74: 3617–3618

    Google Scholar 

  2. Yeager RL, Munroe WGG, Dessau FI (1952) Pyrazinamide (Aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 65: 523–546

    Google Scholar 

  3. Fox W (1981) Whither short-course chemotherapy. Br J Dis Chest 75: 331–357

    Google Scholar 

  4. British Thoracic Association (1982) A controlled trial of six-months chemotherapy for pulmonary tuberculosis: Second report. Results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 126: 460–462

    Google Scholar 

  5. British Thoracic Association (1984) A controlled trial of six months chemotherapy in pulmonary tuberculosis. Final report: Results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 78: 330–336

    Google Scholar 

  6. Snider DE, Graczyk J, Bek E, Rogowski J (1984) Supervised six-months treatment of newly diagnosed pulmonary tuberculosis using isoniazid, rifampicin and pyrazinamide with and without streptomycin. Am Rev Respir Dis 130: 1091–1094

    Google Scholar 

  7. Hong-Kong Chest Service/British Medical Research Council (1987) Five-year follow-up of a controlled trial of five six-months regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136: 1339–1342

    Google Scholar 

  8. Weiner IM, Tinker JP (1972) Pharmacology of pyrazinamide: Metabolic and renal function studies related to the mechanism of drug induced urate retention. J Pharmacol Exp Ther 180: 411–434

    Google Scholar 

  9. Auscher C, Pasquier C, Pehuet P, Delbarre F (1978) Study of urinary pyrazinamide metabolites and their action on the renal excretion of xanthine and hypoxanthine in a xanthinuric patient. Biomedicine 28: 129–133

    Google Scholar 

  10. Pitre D, Facino RM, Carini M, Carlo A (1981) In vitro, biotransformation of pyrazinamide by rat liver: Identification of a new metabolite. Pharmacol Res Commun 13: 351–362

    Google Scholar 

  11. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K (1987) Rapid and simultaneous determination of pyrazinamide and its major metabolites in human plasma by high-performance liquid chromatography. J Chromatogr 413: 342–346

    Google Scholar 

  12. Beretta E, Botturi S, Ferrari P, Tuan G, Zerilli LF (1987) Identification of 5-hydroxypyrazinamide isolated from urine of subjects given pyrazinamide. J Chromatogr 416: 144–149

    Google Scholar 

  13. Yamamoto T, Moriwaki Y, Takahashi S, Hada T, Higashino K (1987) In vitro conversion of pyrazinamide into 5-hydroxypyrazinamide and that of pyrazinoic acid into 5-hydroxypyrazinoic acid by xanthine oxidase from human liver. Biochem Pharmacol 36: 3317–3318

    Google Scholar 

  14. Lacroix C, Poncet P, Lainé G, Guyonnaud C, Ray M, Ménager S, Lafont O (1987) Microdétermination du pyrazinamide et de ses métabolites (acide pyrazinoïque, acide hydroxy-5- pyrazinoïque, hydroxy-5-pyrazinamide, acide pyrazinurique) plasmatiques et urinaires par chromatographie en phase liquide. J Chromatogr 422: 217–225

    Google Scholar 

  15. Yamoaka K, Nakagaw T, Uno T (1978) Statistical moment in pharmacokinetics. J Pharmacokinet Biopharm 6: 547–558

    Google Scholar 

  16. Ellard GA (1969) Absorption, metabolism and excretion of pyrazinamide in man. Tubercle 50: 144–158

    Google Scholar 

  17. Acocella G, Conti R, Grassi C (1985) Pharmacokinetic studies on antituberculosis regimens in humans: I. Absorption and metabolism of the compound used in the initial intensive phase of the short-course regimens: Single administration study. Am Rev Respir Dis 132: 510–515

    Google Scholar 

  18. Lacroix C, Guyonnaud C, Chaou M, Duwoos H, Lafont O (1988) Interaction between allopurinol and pyrazinamide. Eur Respir J 1: 807–811

    Google Scholar 

  19. Ellard GA, Haslam RM (1976) Observations on the reduction of the renal elimination of urate in man caused by the administration of pyrazinamide. Tubercle 57: 97–103

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lacroix, C., Phan Hoang, T., Nouveau, J. et al. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects. Eur J Clin Pharmacol 36, 395–400 (1989). https://doi.org/10.1007/BF00558302

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00558302

Key words

Navigation